TRIM59 and glioma: Both erlotinib and Roscovitine treatments markedly inhibited TRIM59 nuclear translocation (Fig. 8a and Supplementary Fig. 14a), p-STAT3 (Fig. 8a and Supplementary Fig. 14a), PIM1 mRNA expression (Fig. 8b and Supplementary Fig. 14b), and glioma sphere formation (Fig. 8c), but increased mH2A1 protein levels (Fig. 8a and Supplementary Fig. 14a), validating our observations in LN229/EGFR GBM cells (Fig. 1a, d).